Interestingly, visfatin was recently proposed as a potential serum biomarker related to the degree of hepatic steatosis and fibrosis among pediatric obese patients diagnosed by non-invasive methods (abdominal ultrasound and transient elastography with liver stiffness and controlled attenuation parameter) [117]. The gene discussed is NAMPT; the disease is fatty liver disease.